Ann: Appendix 4E & Annual Report, page-23

What are peoples thoughts on the significance of these new cardio-oncology guidelines from the European Society of Cardiology (ESC) for our cardio-protection data?

A/Prof Aaron Sverdlov who recently met with Dr T seems to think it's a big deal for the field of cardio-oncology.

Seems like the presentation of these guidelines at the ESC2022 conference (which is happening now) has generated quite a bit of excitement - just go and look at what A/Prof Sverdlov is posting and retweeting regarding these guidelines.

I think this bodes well for the submission of data to a top journal that sheds some light on the cardio-protective potential of Zantrene, but has anyone read these guidelines closely?

I wonder are there any other golden nuggets of information within the guidelines that have implications for Zantrene or RAC - apart from the fact that there seems to be a huge amount of interest in this area.

If any of you are speaking to Dr T perhaps ask him for his thoughts. I bet he will be reading these guidelines with interest.